Idorsia Ltd. (IDRSF)
5.38
0.00 (0.00%)
USD |
OTCM |
Oct 15, 16:00
Idorsia Research and Development Expense (Quarterly) : 31.45M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.45M |
| March 31, 2026 | 27.75M |
| December 31, 2025 | 33.91M |
| September 30, 2025 | 28.19M |
| June 30, 2025 | 24.98M |
| March 31, 2025 | 28.31M |
| December 31, 2024 | 36.06M |
| September 30, 2024 | 35.67M |
| June 30, 2024 | 38.00M |
| March 31, 2024 | 33.74M |
| December 31, 2023 | 64.53M |
| September 30, 2023 | 70.11M |
| June 30, 2023 | 84.11M |
| March 31, 2023 | 96.94M |
| December 31, 2022 | 104.71M |
| September 30, 2022 | 86.13M |
| June 30, 2022 | 97.17M |
| March 31, 2022 | 99.52M |
| December 31, 2021 | 133.72M |
| Date | Value |
|---|---|
| September 30, 2021 | 98.71M |
| June 30, 2021 | 100.33M |
| March 31, 2021 | 104.18M |
| December 31, 2020 | 97.53M |
| September 30, 2020 | 97.34M |
| June 30, 2020 | 100.10M |
| March 31, 2020 | 96.27M |
| December 31, 2019 | 108.05M |
| September 30, 2019 | 105.03M |
| June 30, 2019 | 106.31M |
| March 31, 2019 | 105.32M |
| December 31, 2018 | 121.42M |
| September 30, 2018 | 103.17M |
| June 30, 2018 | 72.99M |
| March 31, 2018 | 70.86M |
| December 31, 2017 | 72.18M |
| September 30, 2017 | 57.57M |
| June 30, 2017 | |
| March 31, 2017 | 90.57M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 593.46M |
| AC Immune SA | 13.25M |
| CRISPR Therapeutics AG | 64.95M |